Association between KSHV-Specific Humoral and T Cell Responses with Recurrence of HIV-Associated Kaposi Sarcoma.
Kaposi sarcoma
Kaposi sarcoma-associated herpes virus
T cell responses
antibodies
recurrence
sustained remission
Journal
Tropical medicine and infectious disease
ISSN: 2414-6366
Titre abrégé: Trop Med Infect Dis
Pays: Switzerland
ID NLM: 101709042
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
received:
29
04
2024
revised:
28
05
2024
accepted:
11
06
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
26
6
2024
Statut:
epublish
Résumé
Kaposi sarcoma (KS) is an AIDS-defining angio-proliferative malignancy, with the Kaposi sarcoma-associated herpes virus (KSHV) as its etiologic agent. Upon treatment with chemotherapy, a proportion of HIV-associated KS patients experience disease recurrence within a few months of completing treatment. We aimed at determining whether KSHV-specific adaptive immune responses were associated with KS recurrence upon complete remission. We conducted a prospective cohort study. The primary outcome was the recurrence of HIV-associated KS. An immunofluorescence assay was used to determine anti-KSHV antibodies, an enzyme-linked immunospot was conducted for T cell responses, PCR was carried out to determine KSHV status, and flow cytometry was used for CD4 counting and immunophenotyping. KSHV detection in PBMCs was high and not associated with KS recurrence-free survival (
Identifiants
pubmed: 38922046
pii: tropicalmed9060134
doi: 10.3390/tropicalmed9060134
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIH HHS
ID : K43TW011095
Pays : United States
Organisme : NIH HHS
ID : K43TW011418
Pays : United States